Progyny had its Relative Strength (RS) Rating upgraded from 64 to 72 Thursday — a welcome improvement, but still below the 80 or higher score you look for.
Can You Really Time The Stock Market?
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
History reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Progyny can continue to show renewed price strength and clear that threshold.
Progyny is trying to complete a consolidation with a 26.76 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Progyny saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 5% to 31%. Revenue rose from 2% to 11%. Keep an eye out for the company's next round of numbers on or around May 7.
Progyny holds the No. 4 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
